2,601 Stryker Corporation $SYK Shares Sold by Foresight Capital Management Advisors Inc.

Foresight Capital Management Advisors Inc. decreased its position in Stryker Corporation (NYSE:SYK) by 66.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,294 shares of the medical technology company’s stock after selling 2,601 shares during the quarter. Foresight Capital Management Advisors Inc.’s holdings in Stryker were worth $356,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Mitchell Mcleod Pugh & Williams Inc. raised its position in shares of Stryker by 1.2% during the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock valued at $880,000 after acquiring an additional 31 shares in the last quarter. Community Bank & Trust Waco Texas lifted its stake in Stryker by 2.3% during the second quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock worth $439,000 after purchasing an additional 31 shares during the last quarter. Cornerstone Financial Management LLC lifted its stake in Stryker by 66.0% during the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after purchasing an additional 31 shares during the last quarter. NWF Advisory Services Inc. boosted its holdings in Stryker by 2.3% in the second quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock worth $463,000 after purchasing an additional 33 shares during the period. Finally, Harold Davidson & Associates Inc. boosted its holdings in Stryker by 0.4% in the first quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock worth $2,848,000 after purchasing an additional 34 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by insiders.

Stryker Trading Down 1.5%

Shares of Stryker stock opened at $301.59 on Wednesday. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $389.33. The business’s 50 day simple moving average is $294.70 and its 200-day simple moving average is $325.45.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Wednesday, September 30th.

Analyst Ratings Changes

SYK has been the subject of several recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. JPMorgan Chase & Co. dropped their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. TD Cowen reduced their price target on shares of Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research report on Tuesday, September 22nd. Raymond James Financial set a $370.00 price target on shares of Stryker in a report on Friday, July 31st. Finally, Canaccord Genuity Group lowered their price objective on shares of Stryker from $400.00 to $385.00 and set a “buy” rating for the company in a research report on Friday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $369.00.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.